Facing cancer threats from all around, OncoDxRx launched a proprietary 'Gene-to-Drug' technology

OncoDxRx has shown its proprietary genetic profiling could lead to breakthroughs in diagnosis and therapy for common cancers. End Quote

(1888PressRelease) January 22, 2024 - Facing a variety of cancer threats from different directions, OncoDxRx recently launched a new gene-to-drug assay that can provide rapid drug efficacy results to patients with limited treatment options.

The technology, PGA (for Patient-derived Gene expression-informed Anticancer drug efficacy), has been recently operated by a partner laboratory, and is capable of delivering a list of effective drugs to patients in progressive disease.

The trial involved a hybrid configuration for PGA— or two separate components of the workflow combined into one test. This includes the wet-lab cell-free mRNA (cfmRNA) profiling, biomarker quantification and the dry-lab computation with drug screening, matching and classification.

OncoDxRx said that PGA delivered drug efficacy data "in challenging clinical scenarios, achieving favorable and effective outcomes." The liquid biopsy company described the world-first test as a "one of its kind".

PGA provides a non-invasive, real-time, longitudinal tool, capable of rapid sample-to-report within 5 days, in challenging clinical settings, and with high throughput," OncoDxRx says in a statement. The company added that it complements NGS biomarker testing with a "minimized economics and logistics footprint" that can benefit patients who are not responding to current therapies.

The recent PGA test comes as the standard-of-care biomarker testing faces real-world challenges that only 20-30% of cancer patients eligible for targeted therapy or immunotherapy following biomarker tests. Amid the ongoing gap-filling for NGS-based biomarker testing, PGA also has advantages in workflow, cost, turnaround and implementation.

OncoDxRx maintains multiple transformative and exclusive product pipelines, which, since incorporation, has kept quite impressive in achieving the company's milestones. The valuable assets in play over the past two years include the PGA, OncoMRD, and the MCED (multi-cancer early detection) tests.

###

space

Other Related Press Releases